A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Ebiomedicine
Hoyer, K K; Hablesreiter, R R; Inoue, Y Y; Yoshida, K K; Briest, F F; Christen, F F; Kakiuchi, N N; Yoshizato, T T; Shiozawa, Y Y; Shiraishi, Y Y; Striefler, J K JK; Bischoff, S S; Lohneis, P P; Putter, H H; Blau, O O; Keilholz, U U; Bullinger, L L; Pelzer, U U; Hummel, M M; Riess, H H; Ogawa, S S; Sinn, M M; Damm, F F
Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc
Weisman, Paul S PS; Ng, Charlotte K Y CK; Brogi, Edi E; Eisenberg, Rachel E RE; Won, Helen H HH; Piscuoglio, Salvatore S; De Filippo, Maria R MR; Ioris, Rafael R; Akram, Muzaffar M; Norton, Larry L; Weigelt, Britta B; Berger, Michael F MF; Reis-Filho, Jorge S JS; Wen, Hannah Y HY
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Nature Communications
Witkiewicz, Agnieszka K AK; McMillan, Elizabeth A EA; Balaji, Uthra U; Baek, GuemHee G; Lin, Wan-Chi WC; Mansour, John J; Mollaee, Mehri M; Wagner, Kay-Uwe KU; Koduru, Prasad P; Yopp, Adam A; Choti, Michael A MA; Yeo, Charles J CJ; McCue, Peter P; White, Michael A MA; Knudsen, Erik S ES